Rights of chronic renal failure patients undergoing chronic dialysis therapy

Nephrology Dialysis Transplantation

Volumn 19, Issue 1, 2004, Pages 30-38

  Andreucci, Vittorio E ^a,d   Kerr, David N S ^b   Kopple, Joel D ^c  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b KIDNEY RESEARCH UK   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NONE   (Italy)

Author keywords

Dialysis patients; Patients' needs; Patients' rights; Renal patients

Indexed keywords

ALUMINUM HYDROXIDE; ANTIHYPERTENSIVE AGENT; CALCITRIOL; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; CARBONIC ACID; CITRATE CALCIUM; CYANOCOBALAMIN; DIALYSIS FLUID; ERYTHROPOIETIN; FOLIC ACID; LANTHANUM; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PARATHYROID HORMONE; PHOSPHATE; RECOMBINANT ERYTHROPOIETIN; SEVELAMER; VITAMIN;

ANEMIA; BLOOD FLOW VELOCITY; BONE DISEASE; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CONSTIPATION; DEMENTIA; DEPRESSION; DIALYSIS MEMBRANE; ECONOMIC ASPECT; ETHNOLOGY; HEALTH CARE ACCESS; HEALTH CARE FACILITY; HEALTH CARE NEED; HEALTH CARE ORGANIZATION; HEMODIALYSIS; HOSPITAL CARE; HUMAN; HYPERCALCEMIA; HYPERTENSION; KIDNEY TRANSPLANTATION; LONG TERM CARE; MEDICAL AUDIT; MEDICAL DECISION MAKING; MEDICAL DOCUMENTATION; PATIENT RIGHT; PATIENT SELECTION; PERITONEAL DIALYSIS; POLITICS; PRIORITY JOURNAL; PRIVACY; PROTEIN CALORIE MALNUTRITION; PURE RED CELL ANEMIA; RENAL OSTEODYSTROPHY; REVIEW; SOCIAL ASPECT; TREATMENT PLANNING; VASCULAR ACCESS;

HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; PATIENT ADVOCACY; PATIENT PARTICIPATION; PATIENT RIGHTS; PATIENT SELECTION; PERITONEAL DIALYSIS; RENAL DIALYSIS;

EID: 0347917082     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfg531     Document Type: Review

References (83)

1. Peters J. Renal Services for Dialysis: Commissioner and Provider Perspectives. National Kidney Research Fund, Peterborough, UK, 2002
2. Vladeck BC. Learn nothing, forget nothing - the Medicare Commission redux. N Engl J Med 2001; 345: 456-458
3. Wilensky GR. Medicare reform - now is the time. N Engl J Med 2001; 345: 458-462
4. The USRDS Dialysis Morbidity and Mortality Study: Wave 2. United States Renal Data System. Am J Kidney Dis 1997; 30: S67-S85
5. Charatan F. Bush proposes Medicare reform. BMJ 2003; 326: 570
6. Lamping DL, Constantinovici N, Roderick P et al. Clinical outcomes, quality of life, and costs in the North Thames Dialysis Study of elderly people on dialysis: a prospective cohort study. Lancet 2000; 356: 1543-1550
7. Towards an Equitable Renal Service. A Commissioning Framework for End Stage Renal Failure. A Kidney Alliance Report, UK. National Kidney Research Fund, Peterborough, UK, 2001
8. A patient Bill of Rights. AHA Management Advisory 1973. American Hospital Association USA (http://www.aha.org/resource/pbillofrights.asp)
9. Transplant Recipients Bill of Rights and Responsabilities. Action Council Executive Committee 1999/2000. American Society of Transplantation and National Kidney Foundation, USA
10. Definizione dei requisiti strutturali tecnologici e organizzativi minimi per l'autorizzazione alla realizzazione e all'esercizio delle attività sanitarie e/o socio-sanitarie delle strutture pubbliche e private. Boll Uff Regione Campania 2002; 2: 54-55
11. NKF-DOQI clinical practice guidelines for hemodialysis adequacy. National Kidney Foundation. Am J Kidney Dis 1997; 30: S15-S66
12. Pierratos A, Ouwendyk M, Francoeur R et al. Nocturnal hemodialysis: three-year experience. J Am Soc Nephrol 1998; 9: 859-868
13. Ledebo I, Lameire N, Charra B et al. Improving the outcome of dialysis - opinion vs scientific evidence. Report on the Dialysis Opinion Symposium at the ERA-EDTA Congress, 6 September 1999, Madrid. Nephrol Dial Transplant 2000; 15: 1310-1316
14. Pisoni RL, Young EW, Dykstra DM et al. Vascular access use in Europe and the United States: results from the DOPPS. Kidney Int 2002; 61: 305-316
15. Pisoni RL. Vascular access use and outcomes: results from the DOPPS. Contrib Nephrol 2002; 137: 13-19
16. Young EW, Dykstra DM, Goodkin DA, Mapes DL, Wolfe RA, Held PJ. Hemodialysis vascular access preferences and outcomes in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Int 2002; 61: 2266-2271
17. Rayner HC, Pisoni RL, Gillespie BM et al. Creation, cannulation and survival of arterio-venous fistulae - data from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Int 2003; 63: 323-330
18. NKF-DOQI clinical practice guidelines for vascular access. National Kidney Foundation-Dialysis Outcomes Quality Initiative. Am J Kidney Dis 1997; 30: S150-S191
19. Dhingra RK, Young EW, Hulbert-Shearon TE, Leavey SF, Port FK. Type of vascular access and mortality in U.S. hemodialysis patients. Nephrol Dial Transplant 2001; 60: 1443-1451
20. Kimmel PL, Weihs K, Peterson RA. Survival in hemodialysis patients: the role of depression. J Am Soc Nephrol 1993; 4: 12-27
21. Lopes AA, Bragg J, Young E et al. Depression as a predictor of mortality and hospitalization among hemodialysis patients in the United States and Europe. Kidney Int 2002; 62: 199-207
22. Koo JR, Yoon JW, Kim SG et al. Association of depression with malnutrition in chronic hemodialysis patients. Am J Kidney Dis 2003; 41: 1037-1042
23. Held PJ, Port FK, Wolfe RA et al. The dose of hemodialysis and patient mortality. Kidney Int 1996; 50: 550-556
24. McCullough KP, Young EW, Canaud BJ et al. URREA. Delivered dialysis dose predicts mortality for hemodialysis patients in US and Europe. J Am Soc Nephrol 2000; 11: 325A
25. Port FK, Ashby VB, Dhingra RK, Roys EC, Wolfe RA. Dialysis dose and body mass index are strongly associated with survival in hemodialysis patients. J Am Soc Nephrol 2002; 13: 1061-1066
26. Port FK, Wolfe RA. Dialysis dose and patient outcomes: Can results from observational studies by integrated with results from the HEMO study? Semin Dials 2003; 16: 13-16
27. Eknoyan G, Beck GJ, Cheung AK et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347: 2010-2019
28. Hull AR. The 1989 morbidity and mortality meeting: how far have we come? Am J Kidney Dis 1998, 32: S6-S8
29. Charra B, Calemard E, Ruffet M et al. Survival as an index of adequacy of dialysis. Kidney Int 1992, 41: 1286-1291
30. Blumberg A, Weidmann P, Ferrari P. Effect of prolonged bicarbonate administration on plasma potassium in terminal renal failure. Kidney Int 1992, 41: 369-374
31. Hanly PJ, Pierratos A. Improvement of sleep apnea in patients with chronic renal failure who undergo nocturnal hemodialysis. N Engl J Med 2001; 344: 102-107
32. Lacson E, Diaz-Buxo JA. Daily and nocturnal hemodialysis: how do they stack up? Am J Kidney Dis 2001, 38: 225-239
33. Hakim RM, Held PJ, Stannard DC et al. Effect of the dialysis membrane on mortality of chronic hemodialysis patients. Kidney Int 1996; 50: 566-570
34. Locatelli F, Mastrangelo F, Redaelli B et al. Effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parameters. The Italian Cooperative Dialysis Study Group. Kidney Int 1996; 50: 1293-1302
35. Memoli B, Libetta C, Rampino T et al. Hemodialysis related induction of interleukin-6 production by peripheral blood mononuclear cells. Kidney Int 1992; 42: 320-326
36. Locatelli F, Manzoni C. Treatment modalities in comparison: when do clinical differences emerge? Nephrol Dial Transplant 2000; 15: 29-35
37. Locatelli F, Valderrabano F, Hoenich N, Bommer J, Leunissen K, Cambi V. Progress in dialysis technology: membrane selection and patient outcome. Nephrol Dial Transplant 2000; 15: 1133-1139
38. Memoli B, Marzano L, Bisesti V, Andreucci M, Guida B. Hemodialysis-related lymphomononuclear release of interleukin-12 in patients with end-stage renal disease. J Am Soc Nephrol 1999; 10: 2171-2176
39. Ritz E, Deppisch R, Stier E, Hansch G. Atherogenesis and cardiac death: are they related to dialysis procedure and biocompatibility? Nephrol Dial Transplant 1994; 9: 165-172
40. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-126
41. Perez-Garcia R, Rodriguez-Benitez PO. Why and how to monitor bacterial contamination of dialysate? Nephrol Dial Transplant 2000; 15: 760-764
42. Cianciaruso B, Brunori G, Kopple JD et al. Cross-sectional comparison of malnutrition in continuous ambulatory peritoneal dialysis and hemodialysis patients. Am J Kidney Dis 1995; 26: 475-486
43. Cianciaruso B, Brunori G, Traverso G et al. Nutritional status in the elderly patient with uraemia. Nephrol Dial Transplant 1995; 10: 65-68
44. Leavey SF, McCullough K, Hecking E, Goodkin D, Port FK, Young EW. Body mass index and mortality in 'healthier' as compared with 'sicker' haemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2001; 16: 2386-2394
45. Pifer TB, McCullough KP, Port FK et al. Mortality risk in hemodialysis patients and changes in nutritional indicators: DOPPS. Kidney Int 2002; 62: 2238-2245
46. Brady JP, Hasbargen JA. A review of the-effects of correction of acidosis on nutrition in dialysis patients. Semin Dial 2000; 13: 252-255
47. Kaysen GA, Dubin JA, Muller HG, Rosales LM, Levin NW. The acute-phase response varies with time and predicts serum albumin levels in hemodialysis patients. The HEMO Study Group. Kidney Int 2000; 58: 346-352
48. Memoli B, Minutolo R, Bisesti V et al. Changes of serum albumin and C-reactive protein are related to changes of interleukin-6 release by peripheral blood mononuclear cells in hemodialysis patients treated with different membranes. Am J Kidney Dis 2002; 39: 266-273
49. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. National Kidney Foundation-Dialysis Outcomes Quality Initiative. Am J Kidney Dis 1997; 30: S192-S240
50. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Working Party for European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. Nephrol Dial Transplant 1999; 14: 1-50
51. Pisoni RL. Erythropoetin therapy in Europe: results from the DOPPS. In: Ronco C, La Greca G, eds. Hemodialysis Technology, Contrib Nephrol. Karger, Basel, 2002; 137: 396-402
52. Macdougall IC. An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 2001; 16 [SuppI 3]: S14-S21
53. Casadevall N, Dupuy E, Molho-Sabatier P, Tobelem G, Varet B, Mayeux P. Autoantibodies against erythropoietin in a patient with pure red-cell aplasia. N Engl J Med 1996; 334: 630-633
54. Casadevall N, Nataf J, Viron B et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002; 346: 469-475
55. Gallieni M, Cozzolino M, Carpani P, Zoni U, Brancaccio D. Sevelamer reduces calcium load and maintains a low calcium-phosphorus ion product in dialysis patients. J Nephrol 2001; 14: 176-183
56. Fournier A, Barsoum J, Fickl R, Oprisiu R, El Esper N, Moriniere P. Sevelamer, Ca x P product and vitamin D. Nephrol Dial Transplant 2001; 16: 429-430
57. Hou SH, Zhao J, Ellman CF et al. Calcium and phosphorus fluxes during hemodialysis with low calcium dialysate. Am J Kidney Dis 1991; 18: 217-224
58. Fairweather-Tait S, Hickson K, McGaw B, Reid M. Orange juice enhances aluminium absorption from antacid preparation. Eur J Clin Nutr 1994; 48: 71-73
59. Nolan CR, Califano JR, Butzin CA. Influence of calcium acetate or calcium citrate on intestinal aluminum absorption. Kidney Int 1990; 38: 937-941
60. Coburn JW, Mischel MG, Goodman WG, Salusky IB. Calcium citrate markedly enhances aluminum absorption from aluminum hydroxide. Am J Kidney Dis 1991; 17: 708-711
61. Bakir AA, Hryhorczuk DO, Ahmed S et al. Hyperaluminemia in renal failure: the influence of age and citrate intake. Clin Nephrol 1989; 31: 40-44
62. Taylor GA, Moore PB, Ferrier IN, Tyrer SP, Edwardson JA. Gastrointestinal absorption of aluminium and citrate in man. J Inorg Biochem 1998; 69: 165-169
63. Lin JL, Leu ML. Calcium carbonate can enhance aluminium absorption from aluminium hydroxide in patients with impaired renal function. Nephrol Dial Transplant 1996; 11: 1891-1893
64. Slatopolsky EA, Burke SK, Dillon MA. RenaGel, a non-absorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group. Kidney Int 1999; 55: 299-307
65. Chertow GM, Dillon M, Burke SK et al. A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. Clin Nephrol 1999; 51: 18-26
66. Bleyer AJ, Burke SK, Dillon M et al. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 1999; 33: 694-701
67. Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000; 15: 1014-1021
68. Raggi P. Detection and quantification of cardiovascular calcifications with electron beam tomography to estimate risk in hemodialysis patients. Clin Nephrol 2000; 54: 325-333
69. Schiller LR, Santa Ana CA, Sheikh MS, Emmett M, Fordtran JS. Effect of the time of administration of calcium acetate on phosphorus binding. N Engl J Med 1989; 320: 1110-1113
70. Nelson R. Novel phosphate binder is effective in patients on haemodialysis. Lancet 2002; 360: 1483
71. Hutchison AJ. Calcitriol, lanthanum carbonate, and other new phosphate binders in the management of renal osteodystrophy. Perit Dial Int 1999; 19: S408-S412
72. D'Haese PC, Spasovski GB, Sikole A et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int 2003; 63: 73-78
73. Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin KJ. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest 1984; 74: 2136-2143
74. Delmez JA, Tindira C, Grooms P, Dusso A, Windus DW, Slatopolsky E. Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D. A role for increased sensitivity to calcium. J Clin Invest 1989; 83: 1349-1355
75. Andress DL, Norris KC, Coburn JW, Slatopolsky EA, Sherrard DJ. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 1989; 321: 274-279
76. Gallieni M, Brancaccio D, Padovese P et al. Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Italian Group for the Study of Intravenous Calcitriol. Kidney Int 1992; 42: 1191-1198
77. Martin KJ, Gonzalez EA. Vitamin D analogues for the management of secondary hyperparathyroidism. Am J Kidney Dis 2001; 38: S34-S40
78. Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003; 63: 1483-1490
79. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446-456
80. NKF-DOQI clinical practice guidelines for peritoneal dialysis adequacy. National Kidney Foundation. Am J Kidney Dis 1997; 30: S67-S136
81. Paniagua R, Amato D, Vonesh E et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 2002; 13: 1307-1320
82. Plum J, Gentile S, Verger C et al. Efficacy and safety of a 7.5% icodextrin peritoneal dialysis solution in patients treated with automated peritoneal dialysis. Am J Kidney Dis 2002; 39: 862-871
83. Stigant CE, Bargman JM. What's new in peritoneal dialysis: biocompatibility and continuous flow peritoneal dialysis. Curr Opin Nephrol Hypertens 2002; 11: 597-602